Table 1.

Effects of Sophora tomentosa (25 mg/kg, 50 mg/kg, and 100 mg/kg, po) extract on the levels of glutathione and malondialdehyde, and the activities of antioxidant enzymes in the striatum of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced Parkinson disease (PD) mouse model.

Samples	GSH (nmoL/mg of protein)	GR (mU/mg of protein)	GPx (mU/mg of protein)	SOD (U/mg of protein)	Catalase (U/mg of protein)	MDA (nmoL/mg of protein)
Control	2.54 ± 0.35 *	210.08 ± 12.44 *	4.86 ± 0.43 *	21.90 ± 2.71 *	11.11 ± 1.47 *	4.28 ± 0.23 **
MPTP	1.55 ± 0.25	144.02 ± 9.05	3.30 ± 0.23	12.16 ± 1.35	5.79 ± 0.82	8.11 ± 0.76
MPTP + ST 25 mg/kg	1.82 ± 0.22	145.75 ± 14.98	3.89 ± 0.27	14.48 ± 2.00	5.52 ± 1.02	8.25 ± 0.65
MPTP + ST 50 mg/kg	2.06 ± 0.22	180.04 ± 18.24	4.47 ± 0.54	18.10 ± 2.93	8.69 ± 1.93	6.43 ± 1.12
MPTP + ST 100 mg/kg	2.65 ± 0.14 *	249.23 ± 19.10 ***	5.08 ± 0.47 *	25.69 ± 2.12 ***	11.79 ± 1.17 *	4.52 ± 0.47 **

Data are expressed as mean ± SEM (n = 5). * p < 0.05, ** p < 0.01, *** p < 0.001, compared with MPTP group. Sophora tomentosa was administered for 15 consecutive days until the behavioral tests. MPTP (20 mg/kg, ip) were given two times at 4-h interval daily for 5 days until behavioral tests. GPx: glutathione peroxidase, GR: glutathione reductase, GSH: glutathione, MDA: malondialdehyde, MPTP: 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine, PD: Parkinson disease, SOD: superoxide dismutase, ST: Sophora tomentosa.